| [1] |
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6. |
| [2] |
TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance[J]. Clin Liver Dis (Hoboken), 2018, 12(1): 33-34. DOI: 10.1002/cld.728. |
| [3] |
HOU J, WANG G, WANG F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update)[J]. J Clin Transl Hepatol, 2017, 5(4): 297-318. DOI: 10.14218/JCTH.2016.00019. |
| [4] |
LEVRERO M, POLLICINO T, PETERSEN J, et al. Control of cccDNA function in hepatitis B virus infection[J]. J Hepatol, 2009, 51(3): 581-592. DOI: 10.1016/j.jhep.2009.05.022. |
| [5] |
LAI CL, WONG D, IP P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B[J]. J Hepatol, 2017, 66(2): 275-281. DOI: 10.1016/j.jhep.2016.08.022. |
| [6] |
WIELAND SF, EUSTAQUIO A, WHITTEN-BAUER C, et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids[J]. Proc Natl Acad Sci U S A, 2005, 102(28): 9913-9917. DOI: 10.1073/pnas.0504273102. |
| [7] |
BELLONI L, ALLWEISS L, GUERRIERI F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J]. J Clin Invest, 2012, 122(2): 529-537. DOI: 10.1172/JCI58847. |
| [8] |
NING Q, HAN M, SUN Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)[J]. J Hepatol, 2014, 61(4): 777-784. DOI: 10.1016/j.jhep.2014.05.044. |
| [9] |
BUSTER EH, FLINK HJ, CAKALOGLU Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b[J]. Gastroenterology, 2008, 135(2): 459-467. DOI: 10.1053/j.gastro.2008.05.031. |
| [10] |
LIN SM, YU ML, LEE CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma[J]. J Hepatol, 2007, 46(1): 45-52. DOI: 10.1016/j.jhep.2006.08.021. |
| [11] |
BRUNETTO MR, MARCELLIN P, CHERUBINI B, et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype[J]. J Hepatol, 2013, 59(6): 1153-1159. DOI: 10.1016/j.jhep.2013.07.017. |
| [12] |
BUSTER EH, HANSEN BE, LAU GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa[J]. Gastroenterology, 2009, 137(6): 2002-2009. DOI: 10.1053/j.gastro.2009.08.061. |
| [13] |
MARTINOT-PEIGNOUX M, LAPALUS M, MAYLIN S, et al. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients[J]. J Viral Hepat, 2016, 23(11): 905-911. DOI: 10.1111/jvh.12565. |
| [14] |
MA H, YANG RF, WEI L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients[J]. J Gastroenterol Hepatol, 2010, 25(9): 1498-1506. DOI: 10.1111/j.1440-1746.2010.06282.x. |
| [15] |
MAK LY, WONG DK, CHEUNG KS, et al. Review article: Hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther, 2018, 47(1): 43-54. DOI: 10.1111/apt.14376. |
| [16] |
|
| [17] |
ANGGAKUSUMA, ROMERO-BREY I, BERGER C, et al. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation[J]. Hepatology, 2015, 62(3): 702-714. DOI: 10.1002/hep.27913. |
| [18] |
SAVIDIS G, PERREIRA JM, PORTMANN JM, et al. The IFITMs inhibit Zika virus replication[J]. Cell Rep, 2016, 15(11): 2323-2330. DOI: 10.1016/j.celrep.2016.05.074. |
| [19] |
HUANG IC, BAILEY CC, WEYER JL, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus[J]. PLoS Pathog, 2011, 7(1): e1001258. DOI: 10.1371/journal.ppat.1001258. |
| [20] |
MUNIR M, BERG M. The multiple faces of proteinkinase R in antiviral defense[J]. Virulence, 2013, 4(1): 85-89. DOI: 10.4161/viru.23134. |
| [21] |
MAO R, NIE H, CAI D, et al. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein[J]. PLoS Pathog, 2013, 9(7): e1003494. DOI: 10.1371/journal.ppat.1003494. |
| [22] |
TERENZI F, HUI DJ, MERRICK WC, et al. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56[J]. J Biol Chem, 2006, 281(45): 34064-34071. DOI: 10.1074/jbc.M605771200. |
| [23] |
PICHLMAIR A, LASSNIG C, EBERLE CA, et al. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA[J]. Nat Immunol, 2011, 12(7): 624-630. DOI: 10.1038/ni.2048. |
| [24] |
BIANCO C, MOHR I. Restriction of human cytomegalovirus replication by ISG15, a host effector regulated by cGAS-STING double-stranded-DNA sensing[J]. J Virol, 2017, 91(9): e02483-16. DOI: 10.1128/JVI.02483-16. |
| [25] |
LIU Y, LUO S, HE S, et al. Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins[J]. Virology, 2015, 475: 96-109. DOI: 10.1016/j.virol.2014.11.005. |
| [26] |
NASR N, MADDOCKS S, TURVILLE SG, et al. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production[J]. Blood, 2012, 120(4): 778-788. DOI: 10.1182/blood-2012-01-407395. |
| [27] |
CROSSE KM, MONSON EA, DUMBREPATIL AB, et al. Viperin binds STING and enhances the type-I interferon response following dsDNA detection[J]. Immunol Cell Biol, 2021, 99(4): 373-391. DOI: 10.1111/imcb.12420. |
| [28] |
MACPARLAND SA, MA XZ, CHEN L, et al. Lipopolysaccharide and tumor necrosis factor alpha inhibit interferon signaling in hepatocytes by increasing ubiquitin-like protease 18 (USP18) expression[J]. J Virol, 2016, 90(12): 5549-5560. DOI: 10.1128/JVI.02557-15. |
| [29] |
PIGANIS RA, DE WEERD NA, GOULD JA, et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2[J]. J Biol Chem, 2011, 286(39): 33811-33818. DOI: 10.1074/jbc.M111.270207. |
| [30] |
WANG Y, FAN X, SONG Y, et al. SAMD4 family members suppress human hepatitis B virus by directly binding to the Smaug recognition region of viral RNA[J]. Cell Mol Immunol, 2021, 18(4): 1032-1044. DOI: 10.1038/s41423-020-0431-x. |
| [31] |
TAN G, XU F, SONG H, et al. Identification of TRIM14 as a type I IFN-stimulated gene controlling hepatitis B virus replication by targeting HBx[J]. Front Immunol, 2018, 9: 1872. DOI: 10.3389/fimmu.2018.01872. |
| [32] |
GAO B, DUAN Z, XU W, et al. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain[J]. Hepatology, 2009, 50(2): 424-433. DOI: 10.1002/hep.23011. |
| [33] |
TAN G, XIAO Q, SONG H, et al. Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication[J]. Cell Mol Immunol, 2018, 15(3): 272-281. DOI: 10.1038/cmi.2016.67. |
| [34] |
TAN G, YI Z, SONG H, et al. Type-I-IFN-stimulated gene TRIM5 γ inhibits HBV replication by promoting HBx degradation[J]. Cell Rep, 2019, 29(11): 3551-3563. e3. DOI: 10.1016/j.celrep.2019.11.041. |
| [35] |
ZHU HZ, TIAN RY, XIE QY, et al. TRIM28 Promotes HBV Replication by Inhibition of the Activation of JAK/STAT Signaling Pathway by IFN-α[J]. J Hunan Univ(Natural Sciences), 2018, 45(12): 124-130. DOI: 10.16339/j.cnki.hdxbzkb.2018.12.019. |
| [36] |
LIU G, MA X, WANG Z, et al. Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing[J]. J Biol Chem, 2019, 294(38): 14043-14054. DOI: 10.1074/jbc.RA119.007970. |
| [37] |
YUAN L, JIA Q, YANG S, et al. ADAR1 promotes HBV replication through its deaminase domain[J]. Front Biosci (Landmark Ed), 2020, 25: 710-721. DOI: 10.2741/4830. |
| [38] |
LI T, YANG X, LI W, et al. ADAR1 stimulation by IFN-α downregulates the expression of MAVS via RNA editing to regulate the anti-HBV response[J]. Mol Ther, 2021, 29(3): 1335-1348. DOI: 10.1016/j.ymthe.2020.11.031. |
| [39] |
LIU W, LIANG H, WANG S, et al. Transcriptional response of USP18 predicts treatment outcomes of interferon-alpha in HBeAg-positive chronic hepatitis B patientsefere[J]. J Viral Hepat, 2019, 26(9): 1050-1058. DOI: 10.1111/jvh.13120. |
| [40] |
DOMAGALSKI K, PAWŁOWSKA M, ZALEŚNA A, et al. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus[J]. World J Gastroenterol, 2016, 22(41): 9186-9195. DOI: 10.3748/wjg.v22.i41.9186. |
| [41] |
MAKAROVA OV, MAKAROV EM, LVHRMANN R. The 65 and 110 kDa SR-related proteins of the U4/U6. U5 tri-snRNP are essential for the assembly of mature spliceosomes[J]. EMBO J, 2001, 20(10): 2553-2563. DOI: 10.1093/emboj/20.10.2553. |
| [42] |
LIN W, ZHU C, HONG J, et al. The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing[J]. J Hepatol, 2015, 62(5): 1024-1032. DOI: 10.1016/j.jhep.2014.11.038. |
| [43] |
LI Y, ZHU C, WANG F, et al. Expression of interferon effector gene SART1 correlates with interferon treatment response against hepatitis B infection[J]. Mediators Inflamm, 2016, 2016: 3894816. DOI: 10.1155/2016/3894816. |
| [44] |
LIU Y, NIE H, MAO R, et al. Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA[J]. PLoS Pathog, 2017, 13(4): e1006296. DOI: 10.1371/journal.ppat.1006296. |
| [45] |
IMAM H, KIM GW, MIR SA, et al. Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified hepatitis B virus transcripts[J]. PLoS Pathog, 2020, 16(2): e1008338. DOI: 10.1371/journal.ppat.1008338. |
| [46] |
PARK YK, LEE SY, LEE AR, et al. Antiviral activity of interferon-stimulated gene 20, as a putative repressor binding to hepatitis B virus enhancer Ⅱ and core promoter[J]. J Gastroenterol Hepatol, 2020, 35(8): 1426-1436. DOI: 10.1111/jgh.14986. |
DownLoad:
